Comparative Evaluation of Disk- and Tri Leaflet Valves in Left-Ventricular Assist Devices (LVAD)

Reul, H.; Taguchi, K; Herold, M.; Hb, Lo; Reck, Brian H.; Mückter, Harald; Bj, Messmer; G, Rau

doi:10.1177/039139888801100213

Cited by 17 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we showed previously that calcium deposits were present on the polyurethane surface in rat subdermal implants, implying that calcification can occur without thrombus formation 6, 7. Prior work by others showed that calcium deposits on polyurethane heart valves were localized to flexed regions of the valves 1, 8. It also has been shown that calcium deposits localize to cracking and tearing of the polyurethane 9–11.…”

Section: Introductionmentioning

confidence: 85%

Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties

Alferiev

Stachelek

et al. 2003

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 85%

Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties

Alferiev

Stachelek

et al. 2003

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…A number of innovative devices aimed at improving LV systolic function and/or cardiac output in HF patients have been created and refined through large animal models 22,64–68,70. From comparisons of early LV assist devices64,65 to the development of a totally implantable biventricular assist system,66 large animals have served an integral role in groundbreaking advances in cardiac destination therapies.…”

Section: Developing New Therapeutic Targets In Hfmentioning

confidence: 99%

“…From comparisons of early LV assist devices64,65 to the development of a totally implantable biventricular assist system,66 large animals have served an integral role in groundbreaking advances in cardiac destination therapies. The adaptation of such devices for neonatal and pediatric use has also been possible through large animal models 67.…”

Section: Developing New Therapeutic Targets In Hfmentioning

confidence: 99%

Large Animal Models of Heart Failure

Dixon

Spinale

2009

Circ: Heart Failure

253

125

View full text Add to dashboard Cite

Abstract-Congestive heart failure (HF) is a clinical syndrome, with hallmarks of fatigue and dyspnea, that continues to be highly prevalent and morbid. Because of the growing burden of HF as the population ages, the need to develop new pharmacological treatments and therapeutic interventions is of paramount importance. Key Words: myocardial infarction Ⅲ myocardial remodeling Ⅲ overload states Ⅲ rapid pacing C ongestive heart failure (HF) is a constellation of symptoms, with hallmarks of fatigue and dyspnea, which continues to be a highly prevalent and morbid clinical syndrome. Although the etiologic underpinnings of HF can be diverse, common pathophysiologic features include changes in left ventricle (LV) structure, function, and neurohormonal activation. The impact of HF will undoubtedly become even more substantial as the population ages. Accordingly, the need to develop new pharmacological treatments and therapeutic interventions for HF is of paramount importance. The journey from discovery, to understanding, to clinical application of the biological basis of HF is one that can only be traveled with the use of large animal models that recapitulate this clinical phenotype.The current pharmacological armamentarium in the treatment of HF includes angiotensin-converting enzyme inhibitors, aldosterone antagonists, and angiotensin and ␤-adrenergic receptor blockade. 1 Although inhibition of the renin-angiotensin-aldosterone and sympathetic adrenergic systems have provided clear benefit to those suffering from HF, the disease process nonetheless continues. Therefore, further research is required to find additional pathways and mechanisms to target in the battle against HF. The Need for Large Animal Models of HFSignificant insight into the molecular and cellular basis of cardiovascular biology has come from small animal models, particularly mice. However, significant differences exist with regard to cardiac characteristics such as heart rate, oxygen consumption, adrenergic receptor ratios, and response to loss of regulatory proteins, when mice are contrasted to humans. 2,3 Moreover, contractile protein expression, critical to the excitation-contraction coupling process, seems to differ between the 2 species, as evidenced by their differing predominant myosin isoforms. 2 Finally, evidence exists of significant phenotypic differences between mouse and human stem cells. 3 Consequently, extrapolation of murine systems, particularly after induction of cardiovascular stress, becomes problematic when making interpretations of human HF pathophysiology. Therefore, large animal models of HF, which more closely approximate human physiology, function, and anatomy, are essential to develop the discoveries from murine models into clinical therapies and interventions for HF.This review aims to summarize some of the more frequently used large animal models, which recapitulate the clinical HF phenotype arising from the common clinical etiologies of myocardial ischemia/infarction, ventricular overload states, and dilated cardiomyopath...

show abstract

“…In addition, the tendency for thrombus to develop in miniatured valves and pumps creates the need for the development of a ventricular assist device for infants and neonates [3]. In a clinical trial, we started to apply the new HIAMedos system in selected patients since favorable results from in vitro evaluation and animal experiments were reported [5,7,12,15]. Heretofore there have been no publications about HIA-Medos application in patients.…”

Section: Case Reportmentioning

confidence: 99%

Successful Treatment of Postoperative Right Ventricular Heart Failure with the HIA-Medos-Assist System in a 2-Year-Old Girl

et al. 1999

View full text Add to dashboard Cite

One year after total correction of tetralogy of Fallot, reoperation was performed in a 2-year-old infant because of an aneurysm of the right ventricular outflow tract. After removal of the aneurysm, massive right ventricular failure occurred. Maximal medical inotropic support could not reestablish sufficient right ventricular function. Therefore, it was decided to implant the new HIA-Medos system as a right ventricular assist. In the postoperative period, echocardiographic controls showed increasing contractility of the right ventricle. The assist system was removed after 3 days and the infant was discharged in good condition on the 22nd postoperative day.

show abstract

Comparative Evaluation of Disk- and Tri Leaflet Valves in Left-Ventricular Assist Devices (LVAD)

Cited by 17 publications

References 1 publication

Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties

Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties

Large Animal Models of Heart Failure

Successful Treatment of Postoperative Right Ventricular Heart Failure with the HIA-Medos-Assist System in a 2-Year-Old Girl

Contact Info

Product

Resources

About